2021
DOI: 10.3389/fped.2021.713091
|View full text |Cite
|
Sign up to set email alerts
|

A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults

Abstract: Pediatric diseases treated by allogeneic hematopoietic stem cell transplantation (alloHCT) are complex and associated with significant comorbidities and medication requirements that can complicate the transplant process. It is critical to reconcile pre-transplant concomitant medications (pcon-meds) in the weeks prior to alloHCT and to consider the potential for pcon-meds to cause harmful drug-drug interactions (DDIs) or overlapping toxicities with conditioning agents. In this perspective, we describe a systema… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…For seizure prophylaxis, all subjects received levetiracetam beginning 24 h prior to the first dose of busulfan through 24 h post the last dose of busulfan. Moderate or potent enzyme inhibitors or inducers were not allowed during busulfan-based conditioning and discontinued prior to conditioning based on recommendations published by Winger et al [ 8 ].…”
Section: Methodsmentioning
confidence: 99%
“…For seizure prophylaxis, all subjects received levetiracetam beginning 24 h prior to the first dose of busulfan through 24 h post the last dose of busulfan. Moderate or potent enzyme inhibitors or inducers were not allowed during busulfan-based conditioning and discontinued prior to conditioning based on recommendations published by Winger et al [ 8 ].…”
Section: Methodsmentioning
confidence: 99%